CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel(†)

BACKGROUND: Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and CYP2C8*3 genotype. PATIENTS AND METHODS: Demographic, treatment, and toxi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hertz, D. L., Roy, S., Motsinger-Reif, A. A., Drobish, A., Clark, L. S., McLeod, H. L., Carey, L. A., Dees, E. C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660078/
https://ncbi.nlm.nih.gov/pubmed/23413280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt018
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller